# Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

> **NCT05838092** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **RHEACELL GmbH & Co. KG** · enrollment: 9 (actual)

## Conditions studied

- Epidermolysis Bullosa

## Interventions

- **DRUG:** allo-APZ2-OTS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05838092
- **Lead sponsor:** RHEACELL GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-18
- **Primary completion:** 2025-08-29
- **Final completion:** 2026-07
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05838092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05838092, "Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05838092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*